Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study

被引：0

作者：

Bartlett, Nancy L. ^{[1
]}

Sehn, Laurie H. ^{[2
,3
]}

Matasar, Matthew ^{[4
]}

Schuster, Stephen J. ^{[5
]}

Assouline, Sarit ^{[6
]}

Giri, Pratyush ^{[7
]}

Kuruvilla, John ^{[8
]}

Canales, Miguel ^{[9
]}

Dietrich, Sascha ^{[10
]}

Fay, Keith ^{[11
,12
]}

Ku, Matthew ^{[13
]}

Nastoupil, Loretta ^{[14
]}

Wei, Michael C. ^{[15
]}

Yin, Shen ^{[15
]}

To, Iris ^{[15
]}

Huang, Huang ^{[16
]}

Min, Juliana ^{[17
]}

Bolen, Christopher R. ^{[15
]}

Penuel, Elicia ^{[15
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Washington Univ, Siteman Canc Ctr, Sch Med, St Louis, MO USA

[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Mem Sloan Kettering Canc Ctr, New York, NY USA

[5] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[6] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada

[7] Royal Adelaide Hosp, Adelaide, SA, Australia

[8] Princess Margaret Canc Ctr, Toronto, ON, Canada

[9] Hosp Univ La Paz, Madrid, Spain

[10] Heidelberg Univ, Heidelberg, Germany

[11] St Vincents Hosp, Sydney, NSW, Australia

[12] Royal North Shore Hosp, Sydney, NSW, Australia

[13] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] Genentech Inc, San Francisco, CA USA

[16] Hoffmann La Roche Ltd, Mississauga, ON, Canada

[17] Roche Prod Ltd, Welwyn Garden City, Herts, England

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

IBCL; mosunetuzumab; bispecific antibody; relapsed/refractory; follicular lymphoma; Phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-458

引用

页码：S453 / S453

页数：1

共 12 条

[11] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Bennouna, Jaafar
Lang, Istvan
Valladares-Ayerbes, Manuel
Boer, Katalin
Adenis, Antoine
Escudero, Pilar
Kim, Tae-You
Pover, Gillian M.
Morris, Clive D.
Douillard, Jean-Yves
INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
[12] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
Jaafar Bennouna
Istvan Lang
Manuel Valladares-Ayerbes
Katalin Boer
Antoine Adenis
Pilar Escudero
Tae-You Kim
Gillian M. Pover
Clive D. Morris
Jean-Yves Douillard
Investigational New Drugs, 2011, 29 : 1021 - 1028

← 1 2 →